Symbols

RCEL

AVITA Medical·NASDAQ

--(--)

RCEL fundamentals

RCEL Q4 2025 Earnings

AVITA Medical (RCEL) released its earnings on Feb 12, 2026: revenue was 17.43M (YoY -4.29%), missed estimates; EPS was -0.38 (YoY +13.64%), missed estimates.

Revenue / YoY

17.43M

-4.29%

EPS / YoY

-0.38

+13.64%

Report date

Feb 12, 2026

RCEL Earnings Call Summary for Q4,2025

Revenue Growth: 2025 full year revenue $71.6M (+11% YoY), with 2026 guidance of $80-85M driven by utilization normalization and multiproduct adoption.
Reimbursement Resolution: 6/7 MACs published payment rates for RECELL, supporting clinician confidence and utilization.
Financial Flexibility: $18.8M cash post-refinancing; new credit facility removes covenant constraints, enabling execution focus.
Multiproduct Momentum: Early Cohealyx/PermeaDerm adoption in core accounts, with studies nearing completion to support real-world evidence.

Earnings

EPS

Revenue

Revenue & Expenses

RCEL has released its 2025 Q4 earnings report, with revenue of 17.61M, reflecting a YoY change of -4.30%, and net profit of -11.62M, showing a YoY change of -0.28%. The Sankey diagram below clearly presents RCEL's revenue sources and cost distribution.

Key Indicators

AVITA Medical (RCEL) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

AVITA Medical (RCEL)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

AVITA Medical (RCEL)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

AVITA Medical (RCEL)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown